EE3 Cost-Utility Analysis of Xelox Plus Bevacizumab Versus Xelox for Metastatic Colorectal Cancer Treatment in Thailand

Abstract

Authors

C Wanitphisitphan C Kositamongkol K Korphaisarn C Akewanlop V Srimuninnimit P Phisalprapa

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×